Cadrenal Therapeutics, Inc. (CVKD)
(Delayed Data from NSDQ)
$10.70 USD
+2.38 (28.61%)
Updated Sep 12, 2024 03:57 PM ET
After-Market: $10.70 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Cadrenal Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 8 | 0 | -99,999 | -99,999 | -99,999 |
Receivables | 0 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 0 | 1 | NA | NA | NA |
Total Current Assets | 8 | 1 | NA | NA | NA |
Net Property & Equipment | 0 | 0 | NA | NA | NA |
Investments & Advances | 0 | 0 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 0 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 0 | 0 | NA | NA | NA |
Total Assets | 9 | 1 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 0 | 0 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | NA |
Current Portion Capital Leases | 0 | 0 | NA | NA | NA |
Accrued Expenses | 1 | 1 | NA | NA | NA |
Income Taxes Payable | 0 | 0 | NA | NA | NA |
Other Current Liabilities | 0 | 0 | NA | NA | NA |
Total Current Liabilities | 1 | 1 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 1 | NA | NA | NA |
Long-Term Debt | 0 | 0 | NA | NA | NA |
Non-Current Capital Leases | 0 | 0 | NA | NA | NA |
Other Non-Current Liabilities | 0 | 4 | NA | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | NA |
Total Liabilities | 1 | 6 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | NA |
Common Stock (Par) | 0 | 0 | NA | NA | NA |
Capital Surplus | 23 | 1 | NA | NA | NA |
Retained Earnings | -15 | -7 | NA | NA | NA |
Other Equity | 0 | 0 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | 8 | -6 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 9 | 1 | NA | NA | NA |
Total Common Equity | 8 | -6 | 0 | 0 | 0 |
Shares Outstanding | 0.80 | 0.70 | NA | NA | NA |
Book Value Per Share | 9.61 | -7.93 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Cadrenal Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 7 | 8 | 9 | 3 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 5 | 7 | 8 | 9 | 4 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 5 | 7 | 9 | 9 | 4 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 0 | 1 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 1 | 1 | 1 | 1 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1 | 1 | 1 | 1 | 0 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 23 | 23 | 23 | 23 | 16 |
Retained Earnings | -19 | -17 | -15 | -14 | -13 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4 | 6 | 8 | 9 | 3 |
Total Liabilities & Shareholder's Equity | 5 | 7 | 9 | 9 | 4 |
Total Common Equity | 4 | 6 | 8 | 9 | 3 |
Shares Outstanding | 1.00 | 1.00 | 0.80 | 0.80 | 0.80 |
Book Value Per Share | 3.99 | 6.19 | 9.61 | 10.94 | 3.98 |